The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/durvalumab-plus-bcg-earns-fda-nod-bladder-cancer-2026a1000hv5?src=rss
Author :
Publish date : 2026-05-28 20:20:00
Copyright for syndicated content belongs to the linked Source.